The seminar on "Give full play to the main role of enterprise innovation and strengthen the support of pharmaceutical science and technology innovation" was held in Beijing

In the face of policy innovation and transformation and upgrading of the pharmaceutical industry, innovative drug R&D is creating a new pattern in the domestic pharmaceutical industry.

The meeting was conducted in a combined online and offline manner

Workshop scene

Multiple measures to strengthen basic research and enhance original innovation capabilities

"China's new drug research and development has shown a new development.

Chen Kaixian also pointed out that in the context of rapid development, we are also clearly aware that although the number of innovative drugs in China has increased significantly, the original innovation is insufficient

How can society create better conditions for innovation? Song Ruilin, executive chairman of the China Pharmaceutical Innovation Promotion Association, suggested that a true whole-chain ecological environment should be built to support the sustainability of innovation activities

"Medical innovation has always been closely linked to international cooperation.

Song Ruilin

Strengthen the position of the main body of the enterprise and enhance the innovation ability of the enterprise

Mao Shanhong, a distinguished expert from the Beijing Municipal Government, the development director of the Beijing Economic and Technological Development Zone Management Committee, a professor at Capital Medical University, and a doctoral tutor, said that pharmaceutical companies are the mainstay of pharmaceutical innovation.

Mao Shanhong

"Many pharmaceutical companies in Beijing Economic Development Zone have also been struggling to innovate in medicine

Zhao Kun, a researcher at the Health Development Research Center of the National Health Commission and deputy director of the National Health Commission’s Drug and Health Technology Comprehensive Evaluation Center, believes that to enhance the R&D and innovation capabilities of enterprises, the supervision of biomedicine should be strengthened

Pay attention to the patent protection system and tap the potential of human resources

Li Mingde, a doctoral supervisor of the Graduate School of the Chinese Academy of Social Sciences and a member of the National Intellectual Property Expert Advisory Committee, said that to promote the R&D and innovation of corporate drugs requires not only supporting elements such as policies, capital, talents, and land, but also the support of the intellectual property system

Li Mingde

Liu Guoen, dean of Peking University's Institute for Global Health Development, chairman of the Academic Committee of Peking University's National Development Research Institute, and director of Peking University's China Center for Health Economics, believes that personal potential is the most precious source of innovation

Scan the QR code to enter the live broadcast room to watch